A Phase I Open Label Study of the biodistribution, pharmacokinetcis and dosimetry of Ra223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases
- Submitting institution
-
King's College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 97824153
- Type
- D - Journal article
- DOI
-
10.2967/jnumed.115.157123
- Title of journal
- Journal of Nuclear Medicine
- Article number
- -
- First page
- 1304
- Volume
- 56
- Issue
- 9
- ISSN
- 0161-5505
- Open access status
- Out of scope for open access requirements
- Month of publication
- September
- Year of publication
- 2015
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- 1 - Clinical Medicine
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
6
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Radium-223 dichloride (223RaCl2) is the first successful medical application of targeted alpha-particle radiotherapy (TaT). This study developed a new method to quantify 223RaCl2 uptake, retention and excretion in men with advanced, treatment-resistant prostate cancer and derive estimates of alpha-particle radiation doses delivered to normal tissues and tumour. The resulting safety data were critical to Phase II/III study design (NCT00459654; NCT00699751) and underpinned global regulatory approval. 223RaCl2 remains the only internationally licensed TaT. New data from this work increased understanding of the mechanism of action of TaT and provided the rationale for subsequent trials combining 223RaCl2 with other anti-cancer treatments.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
